U.S., April 14 -- ClinicalTrials.gov registry received information related to the study (NCT07524855) titled 'A Study of HLD-0117 in Patients With Metastatic Breast Cancer' on April 06.
Brief Summary: Assessment of the safety and efficacy of HLD-0117 as monotherapy in patients with estrogen receptor positive (ER+) metastatic breast cancer (MBC) or locally advanced breast cancer that have progressed on prior systemic therapies.
Study Start Date: March 31
Study Type: INTERVENTIONAL
Condition:
Metastatic Breast Cancer
Intervention:
DRUG: HLD-0117
A treatment cycle consists of 28 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any...